Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07803523 Kinesiophobia Associated With Fatigue in Patients With Multiple Scleros… |
Kinesiophobia Associated With Fat… | SEP | À vérifier | COMPLETED | En attente / non publié | Dokuz Eylul University | Turkey (Türkiye) · Department of Physical Medicine an… | 2025-05-28 → 2026-01-30 | Ouvrir |
| NCT07517185 HiHat — The HIt HArd and hiT Early in Multiple Sclerosis Trial |
Sequential treatment with rituxim… | SEP | Phase 2 | RECRUITING | En attente / non publié | Uppsala University | Sweden · Centralsjukhuset Karlstad, Neurologi och Reh… | 2026-09-01 → 2030-12-31 | Ouvrir |
| NCT07503340 Operetta III — A Study to Evaluate Pharmacokinetics, Safety, Tolerabili… |
Ocrelizumab Co-formulated With rH… | SEP | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | Hoffmann-La Roche | Non communiqué | 2026-10-30 → 2031-08-01 | Ouvrir |
| NCT07687693 Simultaneous T2-FLAIR and T1 Brain MRI With ENRAGED FLAIR in Multiple S… |
Simultaneous T2-FLAIR and T1 Brai… | SEP | Non applicable | COMPLETED | En attente / non publié | Region Stockholm | Sweden · Karolinska Universitetssjukhuset, Stockholm,… | 2026-08-10 → 2026-08-31 | Ouvrir |
| NCT07002034 RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Ot… |
RE104 for Injection | Sclérose latérale amyotrophique | Phase 2 | RECRUITING | En attente / non publié | Reunion Neuroscience Inc | United States · Alliance for Multispecialty Research … | 2025-07-30 → 2026-12 | Ouvrir |
| NCT07647510 A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Mya… |
Claseprubart | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Dianthus Therapeutics | United States · Cinical Study Site, Boca Raton, Unite… | 2026-06-29 → 2031-09 | Ouvrir |
| NCT07155850 Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoa… |
Medical device containing Y-90 mi… | Cancer | Non applicable | RECRUITING | En attente / non publié | BetaGlue Therapeutics SpA | Italy, United Kingdom · Fondazione Policlinico Univer… | 2026-02-03 → 2027-02 | Ouvrir |
| NCT05797246 Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) |
Bevacizumab | Cancer | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | AbbVie | United States · National Institutes of Health Clinica… | 2023-08-02 → 2029-01-01 | Ouvrir |
| NCT02573792 Optical Coherence Tomography and Optic Neuritis (OCTON) |
Optical Coherence Tomography and … | SEP | À vérifier | COMPLETED | En attente / non publié | Fondation Ophtalmologique Adolphe… | France · Fondation Ophtalmologique Adolphe de Rothsch… | 2015-10-05 → 2019-07 | Ouvrir |
| NCT03900221 RESPONSE — French Registry for Monitoring Pregnancies for Multiple Scle… |
RESPONSE — French Registry for Mo… | SEP | À vérifier | RECRUITING | En attente / non publié | Hospices Civils de Lyon | France, Martinique · Cabinet médical Dr C. CORNUT-CHA… | 2019-08-12 → 2036-08-12 | Ouvrir |
| NCT04202055 BIOMOG — Immunologic Biomarker Profile of Cerebrospinal Fluid |
BIOMOG — Immunologic Biomarker Pr… | SEP | À vérifier | COMPLETED | En attente / non publié | Centre Hospitalier Universitaire … | France · CHU de Nîmes, Nîmes, France | 2018-01-02 → 2019-08-31 | Ouvrir |
| NCT02433028 SMSC — Swiss Multiple Sclerosis Cohort-Study |
SMSC — Swiss Multiple Sclerosis C… | SEP | À vérifier | RECRUITING | En attente / non publié | University Hospital, Basel, Switz… | Switzerland · Cantonal Hospital Aarau, Aarau, Switzer… | 2012-06 → 2042-01 | Ouvrir |
| NCT06572059 MotorImagery — Upper Extremity Motor Imagery Functional Skills and Qual… |
MotorImagery — Upper Extremity Mo… | SEP | À vérifier | COMPLETED | En attente / non publié | Kahramanmaras Sutcu Imam Universi… | Turkey (Türkiye) · Hatice Adiguzel, Kahramanmaraş, Tu… | 2023-07-07 → 2023-10-30 | Ouvrir |
| NCT01918501 Testing Mitochondria Activity and Blood Lipid Content of Multiple Scler… |
Blood testing | SEP | Non applicable | UNKNOWN | En attente / non publié | Ziv Hospital | Israel · Ziv Medical Center, Safed, Israel | 2013-08 → 2015-07 | Ouvrir |
| NCT06315972 OligoTreat — Combining Clemastine and Aerobic Exercise to Treat Cogniti… |
clemastine (8 mg/day) | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | LMU Klinikum | Non communiqué | 2024-04 → 2028-04 | Ouvrir |
| NCT04042363 ONSTIM — Effect of Transorbital Electrical STIMulation of Optic Nerve o… |
Transorbital electrical stimulati… | SEP | Non applicable | UNKNOWN | En attente / non publié | Centre Hospitalier National d'Oph… | France · Centre Hospitalier National d'Ophtalmologie … | 2019-07-10 → 2022-07 | Ouvrir |
| NCT07526493 Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of… |
Universal CD19 CAR-γδT Cell Injec… | SEP | Phase 1 | RECRUITING | En attente / non publié | Tongji Hospital | China · Tongji Hospital, Tongji Medical College, Huaz… | 2026-04-01 → 2028-12-31 | Ouvrir |
| NCT02040298 ReBUILD — Assessment of Clemastine Fumarate as a Remyelinating Agent in… |
Clemastine | SEP | Phase 2 | COMPLETED | En attente / non publié | University of California, San Fra… | United States · UCSF Multiple Sclerosis Center, San F… | 2014-01 → 2016-04 | Ouvrir |
| NCT06683612 PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS an… |
PIPE-791 | SEP | Phase 1 | COMPLETED | En attente / non publié | Contineum Therapeutics | United Kingdom · Hammersmith Medicines Research, Lond… | 2024-12-09 → 2025-06-12 | Ouvrir |
| NCT06711354 B-cell Depletion in Offspring to Women With MS Under Immunomodulatory T… |
Anti-CD20 Monoclonal Antibody | SEP | À vérifier | UNKNOWN | En attente / non publié | Region Stockholm | Non communiqué | 2025-06 → 2025-12 | Ouvrir |
| NCT04971005 COAST — Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoiet… |
Autologous Hematopoietic Stem Cel… | SEP | Phase 2 | TERMINATED | En attente / non publié | Universitätsklinikum Hamburg-Eppe… | Germany · Universitätsklinikum Hamburg-Eppendorf, Ham… | 2021-08-27 → 2022-02-04 | Ouvrir |
| NCT02807285 Expanded Access Program for Ocrelizumab in Participants With Primary Pr… |
Ocrelizumab | SEP | À vérifier | NO_LONGER_AVAILABLE | En attente / non publié | Hoffmann-La Roche | United States · Abington Neurological Associates, Wil… | Non communiqué | Ouvrir |
| NCT05123703 Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in … |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Australia, Austria, Belgium… | 2022-05-19 → 2029-09-17 | Ouvrir |
| NCT04458688 Investigating the Effect of Ocrelizumab in African Americans and Caucas… |
Investigating the Effect of Ocrel… | SEP | À vérifier | RECRUITING | En attente / non publié | Wayne State University | United States · Wayne State University, Detroit, Unit… | 2021-11-20 → 2030-12 | Ouvrir |
| NCT06526000 Study to Assess Changes in Immunoglobulins in Patients With Relapsing M… |
Study to Assess Changes in Immuno… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis | United States · Novartis Pharmaceuticals, East Hanove… | 2022-10-11 → 2024-02-28 | Ouvrir |